Due to their efficient recognition and lysis of malignant cells, natural killer (NK) cells are
considered as specialized immune cells that can be genetically modified to obtain capable …

Chimeric antigen receptor (CAR) T cell therapy, in which a patient's own T lymphocytes are
engineered to recognize and kill cancer cells, has achieved remarkable success in some …

Remission durability following single-antigen targeted chimeric antigen receptor (CAR) T-
cells is limited by antigen modulation, which may be overcome with combinatorial targeting …

Identification of new markers associated with long-term efficacy in patients treated with CAR
T cells is a current medical need, particularly in diseases such as multiple myeloma. In this …

Chimeric antigen receptor (CAR) T cell therapy has transformed the treatment of
haematological malignancies such as acute lymphoblastic leukaemia, B cell lymphoma and …

Messenger RNA (mRNA) has emerged as a promising therapeutic molecule with numerous
clinical applications in treating central nervous system disorders, tumors, COVID-19, and …

Although chimeric antigen receptor T (CAR-T) cell therapy achieves high remission rates,
challenges (eg, toxicity management and relapse prevention) remain. The major risks are …

Safety assessment in retroviral vector-mediated gene therapy remains challenging. In
clinical trials for different blood and immune disorders, insertional mutagenesis led to …

Background Targeted T-cell therapy has emerged as a promising strategy for the treatment
of hematological malignancies. However, its application to solid tumors presents significant …

Autologous chimeric antigen receptor T-cell (CAR-T) therapies targeting B-cell maturation
antigen (BCMA) have revolutionized the field of multiple myeloma in the same way that the …